Effect of wharton's jelly derived-mesenchymal stem cells in treatment of pediatric with cardiomyopathy

Phase 1

Recruiting

• Conditions: Viral cardiomyopathy.; Viral cardiomyopathy; B33.24

• Registration Number: IRCT20201217049743N1
• Lead Sponsor: Celltech pharmed company

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 5

Inclusion Criteria

20% Time of Diagnosis > 1 y
Candidate for heart transplantation
Heart failure due to idiopathic and acute viral myocarditis
NYHA function class II/III

Exclusion Criteria

Critical aortic stenosis
Severe coarctation
Coronary artery anomalies
Cardiogenic shock

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Assessment of safety. Timepoint: Base and 1 week, 1,3,6,9 months after transplantation. Method of measurement: Physical examination and clinical symptom.;Assessment of tolerability. Timepoint: Base and 1 week, 1,3,6,9 months after transplantation. Method of measurement: Physical examination and clinical symptom.

Secondary Outcome Measures

Name	Time	Method
ProBNP measurement. Timepoint: Base, 1, 3, 6, 9 and 12 months after transplantation. Method of measurement: Lab test.